Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Press release

EQL Pharma's CBDO increases his holding in the company

EQL Pharma

EQL Pharma's Chief Business Development Officer (CBDO), Carl Lindgren, increases his shareholding in the company. On November 14[th], Carl Lindgren has bought 10,000 shares in the Company at an average price of SEK 60.00, a transaction totalling SEK 600,000. The trades were made outside the Stock Market and the shares were bought from the major owner Fårö Capital AB, related to Christer Fåhraeus who is Chairman of the board of EQL Pharma. After the purchases, Lindgren owns a total of 60,000 shares and 100,000 warrants in EQL Pharma.

"EQL is an entrepreneurial company in rapid and profitable growth, and I look forward to contributing to the continued positive development of the company in collaboration with the management, colleagues, and external partners," says Carl Lindgren. "I believe in the company long-term and think it's important to have 'skin in the game,' so it feels very natural to increase my ownership in EQL," concludes Carl Lindgren.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.